Toggle menu

ATTEST2

Start date:
July 2017
End date:
January 2021
Co-ordinated by:
The Stroke Research Team
Main trial site:
NHS Greater Glasgow & Clyde

ATTEST 2 aims to test tenecteplase in a large clinical trial to establish whether it is a better drug than alteplase for use in thrombolysis. This will involve a large number of hospitals in the UK, and possibly overseas. People who are considered suitable for thrombolysis will be allocated at random to receive either the current standard treatment with alteplase, or tenecteplase, and will be followed up for the first 90 days to measure the effects on recovery.
Even if there are no significant differences between between the two drugs, tenecteplase is less expensive and much easier to give to patients than alteplase, needing a single injection only. Alteplase has to be given as an injection followed by a longer injection over an hour. This advantage of tenecteplase alone would have worthwhile benefits to the patient.

Trial Design
Prospective Randomised Open, Blinded End-point (PROBE) – Phase III

Principal Investigator
Dr. Will Whitely, Stroke Medicine, University of Edinburgh & NHS Lothian

Local PI

Dr Matt Reed

Consultant and NRS Career Research Fellow in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

Attitudes towards Research and Research Nurses among the clinical team in an Emergency Department (ED) and Acute Medical Unit (AMU)

Read more

Research on Research

Attitudes towards Research and Research Nurses

Patients commonly present to the Emergency Department with epistaxsis (nose bleed). Standard first aid measures such as applying pressure can often stem bleeding however in more severe cases of epistaxsis further treatment is required.

Read more

NoPac

Novel Use of Tranexamic Acid to Reduce the Need for Nasal Packing

In the Liver Unit at the Royal Infirmary of Edinburgh, we are involved in research to improve the treatment available for people with liver cirrhosis. Cirrhosis of the liver can make people vulnerable to other potentially serious complications including kidney problems.

Read more

AKI in LC Study